Regeneron Pharmaceuticals Inc (REGN) Stock AnalysisREGNStock AnalysisRegeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Regeneron Pharmaceuticals Inc is currently not a good buy due to recent negative catalysts, including a significant trial failure that resulted in an $11 billion market cap loss. The current price is $794.19, which is below the average analyst target of $795, indicating limited upside potential. Additionally, the RSI is at 35.243, suggesting the stock is oversold, but the recent 5-day change of -4.78% raises concerns about further declines.

26 analysts cover REGN: 13 rate it Buy, 12 Hold and 1 Sell. The average price target is 808.50.